Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of “Buy” from Brokerages

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have been given a consensus recommendation of “Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and four have given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $55.40.

Several research firms recently commented on SRRK. HC Wainwright reissued a “buy” rating and issued a $58.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 3rd. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday, March 3rd. Wedbush increased their price objective on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday, April 1st. BMO Capital Markets increased their price objective on Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday, March 4th. Finally, Truist Financial increased their price objective on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd.

Insiders Place Their Bets

In other Scholar Rock news, CEO David Hallal sold 30,615 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $1,517,585.55. Following the completion of the sale, the chief executive officer directly owned 1,639,034 shares of the company’s stock, valued at $81,246,915.38. This trade represents a 1.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mo Qatanani sold 8,484 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $47.07, for a total value of $399,341.88. Following the completion of the sale, the insider directly owned 98,445 shares of the company’s stock, valued at $4,633,806.15. This trade represents a 7.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 117,634 shares of company stock worth $5,673,786. 13.30% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the stock. IFP Advisors Inc increased its stake in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Scholar Rock in the 4th quarter worth $30,000. Summit Securities Group LLC acquired a new stake in shares of Scholar Rock in the 4th quarter worth $31,000. EverSource Wealth Advisors LLC increased its stake in shares of Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after acquiring an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC acquired a new stake in shares of Scholar Rock in the 4th quarter worth $44,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Stock Up 0.6%

NASDAQ SRRK opened at $48.10 on Friday. The business has a fifty day moving average price of $46.17 and a 200 day moving average price of $42.20. Scholar Rock has a one year low of $27.07 and a one year high of $51.63. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95. The company has a market cap of $5.53 billion, a P/E ratio of -14.02 and a beta of 0.68.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period last year, the company earned ($0.64) earnings per share. Research analysts anticipate that Scholar Rock will post -3.13 EPS for the current fiscal year.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).